Alexandria venture investments ranked as #1 most active corporate investor in biopharma for sixth consecutive year

Alexandria's highly strategic venture capital platform is an integral component of the company's unwavering efforts to catalyze innovation in medicine, a national imperative, across its life science ecosystems and since 1996 has enabled its early identification of novel technology platforms and disruptive products that have led to groundbreaking medicines to meet massive unmet medical need pasadena, calif. , jan. 9, 2023 /prnewswire/ -- alexandria venture investments, the strategic venture capital platform of alexandria real estate equities, inc. (nyse: are), the first, preeminent, longest-tenured and pioneering owner, operator and developer of collaborative life science, agtech and technology campuses in aaa innovation cluster locations with over 1,000 tenants, today announced that it was recognized by silicon valley bank in its "healthcare investments and exits: annual report 2022" as the #1 most active corporate investor in biopharma by new deal volume (2021–2022) for the sixth consecutive year.
ARE Ratings Summary
ARE Quant Ranking